Experienced in Thrombocytopenia

Dr. Leslie L. Popplewell

Hematology | Hematology Oncology
City Of Hope Medical Group Of Georgia LLC
600 Celebrate Life Pkwy, 
Newnan, GA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
29 Years of Experience
Experienced in Thrombocytopenia
City Of Hope Medical Group Of Georgia LLC
600 Celebrate Life Pkwy, 
Newnan, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leslie Popplewell is a Hematologist and a Hematologist Oncology provider in Newnan, Georgia. Dr. Popplewell has been practicing medicine for over 29 years and is rated as an Experienced provider by MediFind in the treatment of Thrombocytopenia. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Popplewell is currently accepting new patients.

Her clinical research consists of co-authoring 89 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Midwestern Region Med Center, Inc
Southeastern Regional Medical Center, Inc
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL GROUP OF GEORGIA LLC
600 Celebrate Life Pkwy, Newnan, GA 30265
Other Locations
CITY OF HOPE MEDICAL GROUP OF ILLINOIS PLLC
2520 Elisha Ave, Zion, IL 60099

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase I/II Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase I/II Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: March 06, 2025
Intervention Type: Drug
Study Drugs: Venetoclax, Lenalidomide, Rituximab
Study Phase: Phase 1/Phase 2
Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Autologous Hematopoietic Stem Cell Transplantation for Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL)
Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Autologous Hematopoietic Stem Cell Transplantation for Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL)
Enrollment Status: Recruiting
Publish Date: February 18, 2025
Intervention Type: Procedure, Biological
Study Phase: Phase 1
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Ibrutinib
Study Phase: Phase 2
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Enrollment Status: Completed
Publish Date: October 07, 2025
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Biological, Other, Procedure
Study Drug: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
Study Phase: Phase 1
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Rituximab, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2025
Intervention Type: Biological, Other
Study Drugs: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Study Phase: Phase 1
Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 25, 2025
Intervention Type: Biological, Procedure, Other, Drug
Study Drugs: filgrastim, rituximab, genetically engineered lymphocyte therapy, plerixafor
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

88 Total Publications

Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma.
Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma.
Journal: Transplantation and cellular therapy
Published: January 15, 2025
Similar Doctors
Distinguished in Thrombocytopenia
Dr. Mansoor N. Saleh
Hematology Oncology | Hematology | Oncology
Distinguished in Thrombocytopenia
Dr. Mansoor N. Saleh
Hematology Oncology | Hematology | Oncology
1100 Johnson Ferry Rd Ne, Suite 600, 
Sandy Springs, GA 
 (40.8 miles away)
404-256-4777
Languages Spoken:
English
See accepted insurances

Mansoor Saleh is a Hematologist Oncology specialist and a Hematologist in Sandy Springs, Georgia. Dr. Saleh is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Purpura, Adult Immune Thrombocytopenia, Thrombocytopenia, and Splenectomy.

Distinguished in Thrombocytopenia
Dr. Rao S. Moravineni
Hematology Oncology | Hematology | Oncology
Distinguished in Thrombocytopenia
Dr. Rao S. Moravineni
Hematology Oncology | Hematology | Oncology

Nsh Cancer Institute Professional Services G LLC

1045 Southcrest Dr, Suite 200, 
Stockbridge, GA 
 (29.8 miles away)
678-289-0549
Languages Spoken:
English, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Rao Moravineni is a Hematologist Oncology specialist and a Hematologist in Stockbridge, Georgia. Dr. Moravineni is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Thrombocytopenia, and Lung Cancer. Dr. Moravineni is currently accepting new patients.

Distinguished in Thrombocytopenia
Dr. Aaron J. Schueneman
Hematology Oncology | Hematology | Oncology
Distinguished in Thrombocytopenia
Dr. Aaron J. Schueneman
Hematology Oncology | Hematology | Oncology

Nsh Cancer Institute Professional Services G LLC

1045 Southcrest Dr, Suite 200, 
Stockbridge, GA 
 (29.8 miles away)
678-289-0549
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aaron Schueneman is a Hematologist Oncology specialist and a Hematologist in Stockbridge, Georgia. Dr. Schueneman is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Thrombocytopenia, Childhood Iron Deficiency Anemia, Paget Disease of the Breast, and Acute Mountain Sickness. Dr. Schueneman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Popplewell's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 16 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile